RU2454220C2 - Способ получения твердых дисперсий высококристаллических терапевтических соединений - Google Patents

Способ получения твердых дисперсий высококристаллических терапевтических соединений Download PDF

Info

Publication number
RU2454220C2
RU2454220C2 RU2009109357/15A RU2009109357A RU2454220C2 RU 2454220 C2 RU2454220 C2 RU 2454220C2 RU 2009109357/15 A RU2009109357/15 A RU 2009109357/15A RU 2009109357 A RU2009109357 A RU 2009109357A RU 2454220 C2 RU2454220 C2 RU 2454220C2
Authority
RU
Russia
Prior art keywords
poloxamer
mixture
therapeutic compound
midostaurin
temperature
Prior art date
Application number
RU2009109357/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2009109357A (ru
Inventor
Индраджит ГОШ (US)
Индраджит ГОШ
Дженнифер СНАЙДЕР (US)
Дженнифер СНАЙДЕР
Вэйцинь ТОН (US)
Вэйцинь ТОН
Судха ВИППАГУНТА (US)
Судха ВИППАГУНТА
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2009109357A publication Critical patent/RU2009109357A/ru
Application granted granted Critical
Publication of RU2454220C2 publication Critical patent/RU2454220C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Peptides Or Proteins (AREA)
RU2009109357/15A 2006-08-16 2007-08-14 Способ получения твердых дисперсий высококристаллических терапевтических соединений RU2454220C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82255606P 2006-08-16 2006-08-16
US60/822,556 2006-08-16

Publications (2)

Publication Number Publication Date
RU2009109357A RU2009109357A (ru) 2010-09-27
RU2454220C2 true RU2454220C2 (ru) 2012-06-27

Family

ID=38657762

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009109357/15A RU2454220C2 (ru) 2006-08-16 2007-08-14 Способ получения твердых дисперсий высококристаллических терапевтических соединений

Country Status (16)

Country Link
US (2) US20100038816A1 (https=)
EP (1) EP2054040B1 (https=)
JP (1) JP5546860B2 (https=)
KR (1) KR101462693B1 (https=)
CN (1) CN101516339B (https=)
AT (1) ATE503484T1 (https=)
AU (1) AU2007284615B2 (https=)
BR (1) BRPI0714963A2 (https=)
CA (1) CA2660086C (https=)
DE (1) DE602007013567D1 (https=)
ES (1) ES2363725T3 (https=)
MX (1) MX2009001636A (https=)
PL (1) PL2054040T3 (https=)
PT (1) PT2054040E (https=)
RU (1) RU2454220C2 (https=)
WO (1) WO2008021347A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577348B2 (en) 2014-12-18 2020-03-03 Merck Sharp & Dohme Corp. (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
MX2010011962A (es) * 2008-04-30 2010-11-30 Novartis Ag Proceso continuo para hacer composiciones farmaceuticas.
EP2327706A1 (en) 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN102525879B (zh) * 2010-12-31 2015-01-21 正大天晴药业集团股份有限公司 制备阿瑞匹坦固体分散组合物的方法
BR112016021739B1 (pt) * 2014-03-25 2021-11-03 Genentech, Inc Método para preparar um poloxâmero para uso em um meio de cultura de célula
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
CN108024939B (zh) 2015-08-20 2024-06-07 联合利华知识产权控股有限公司 包封的内酰胺
ES2758300T3 (es) 2015-08-20 2020-05-05 Unilever Nv Solubilidad de lactama mejorada
EP3337451B1 (en) 2015-08-20 2018-12-26 Unilever PLC Improved lactam solubility
CN107848968B (zh) 2015-08-20 2021-06-18 荷兰联合利华有限公司 从乙醛酸制备内酰胺的方法
WO2017029093A1 (en) 2015-08-20 2017-02-23 Unilever Plc Improved lactam solubility
CN107920976A (zh) 2015-08-20 2018-04-17 荷兰联合利华有限公司 改善的内酰胺溶解度
BR112018003082B1 (pt) * 2015-08-20 2021-12-14 Unilever Ip Holdings B.V. Lactama em uma dispersão sólida, método de produção de uma composição compreendendo uma lactama e método de formação de lactama em uma dispersão sólida
JP7021182B2 (ja) * 2016-03-24 2022-02-16 ロケート・バイオ・リミテッド 足場材料、方法および使用
MX383740B (es) * 2016-05-13 2025-03-14 Merck Patent Gmbh Composición de extrusión fundida en caliente que usa un excipiente compresible directo como plastificante.
CN111615389A (zh) 2018-02-01 2020-09-01 科尔沃斯制药股份有限公司 药物调配物
EP3520782A3 (en) * 2018-02-01 2019-11-13 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations containing adenosine a2a receptor antagonists
CN113573712A (zh) 2019-02-18 2021-10-29 斯莱班克制药有限责任公司 尼洛替尼的药物组合物
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN114796149A (zh) * 2022-04-27 2022-07-29 苏州中化药品工业有限公司 一种高生物利用度的双醋瑞因胶囊剂及其制备方法
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153608A1 (en) * 2000-03-17 2003-08-14 Markus Maegerlein Torasemide-containing pharmaceutical preparations

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5837714A (en) * 1997-03-03 1998-11-17 Sanofi Solid pharmaceutical dispersions
ATE232087T1 (de) * 1997-10-27 2003-02-15 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
EP1372611B1 (en) 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
HU229938B1 (en) * 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
US6756381B2 (en) * 2002-02-21 2004-06-29 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 ｖ 억제제 제형
US7498309B2 (en) * 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
CN102127057A (zh) * 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
US20050288481A1 (en) * 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
MX2007002415A (es) * 2004-08-31 2007-04-23 Novartis Ag Uso de midostaurina para el tratamiento de tumores estromales gastrointestinales.
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
JO2897B1 (en) * 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
WO2007068615A2 (en) * 2005-12-14 2007-06-21 F. Hoffmann-La Roche Ag Hcv prodrug formulation
BRPI0622054B8 (pt) * 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US8258137B2 (en) * 2008-01-29 2012-09-04 Katholieke Universiteit Leuven Process for release of biologically active species from mesoporous oxide systems
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
CN107898791A (zh) * 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
EP2618846A1 (en) * 2010-09-24 2013-07-31 Mallinckrodt LLC Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
US9295673B2 (en) * 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153608A1 (en) * 2000-03-17 2003-08-14 Markus Maegerlein Torasemide-containing pharmaceutical preparations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577348B2 (en) 2014-12-18 2020-03-03 Merck Sharp & Dohme Corp. (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
US10710982B2 (en) 2014-12-18 2020-07-14 Merck Sharp & Dohme Corp. (S)-N-(3-6-isopropoxypyridin-3-3YL)-1H-indazol-5-yl)-1-(2-(4-4(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H-yl)-2-oxoethyl)-3(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
US11034673B2 (en) 2014-12-18 2021-06-15 Merck Sharp & Dohme Corp. (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations

Also Published As

Publication number Publication date
MX2009001636A (es) 2009-02-23
WO2008021347A3 (en) 2008-08-07
WO2008021347A2 (en) 2008-02-21
PL2054040T3 (pl) 2011-09-30
CN101516339B (zh) 2012-06-13
CA2660086A1 (en) 2008-02-21
EP2054040B1 (en) 2011-03-30
ES2363725T3 (es) 2011-08-12
DE602007013567D1 (de) 2011-05-12
US8641948B2 (en) 2014-02-04
KR20090042961A (ko) 2009-05-04
PT2054040E (pt) 2011-06-30
US20120190667A1 (en) 2012-07-26
JP2010500411A (ja) 2010-01-07
AU2007284615B2 (en) 2011-10-27
BRPI0714963A2 (pt) 2013-07-30
ATE503484T1 (de) 2011-04-15
AU2007284615A1 (en) 2008-02-21
RU2009109357A (ru) 2010-09-27
KR101462693B1 (ko) 2014-11-17
US20100038816A1 (en) 2010-02-18
CA2660086C (en) 2014-09-16
CN101516339A (zh) 2009-08-26
JP5546860B2 (ja) 2014-07-09
EP2054040A2 (en) 2009-05-06

Similar Documents

Publication Publication Date Title
RU2454220C2 (ru) Способ получения твердых дисперсий высококристаллических терапевтических соединений
RU2491918C2 (ru) Способ грануляции из расплава
US20200261449A1 (en) Pharmaceutical compositions of nilotinib
CN101951891A (zh) 固态药物剂型
CN106232144B (zh) 固体分散体
RU2713428C1 (ru) Частицы, содержащие аморфный эмпаглифлозин, способ их получения и содержащий их лекарственный препарат
JP2010500411A5 (https=)
TW201609195A (zh) 固體抗病毒劑型
AU2016373574B2 (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
RU2430719C2 (ru) Способ приготовления фармацевтических композиций с нестойким пластификатором
US20090023754A1 (en) Modified release famciclovir pharmaceutical compositions
CN106456612A (zh) 经口给药用医药组合物
RU2776962C1 (ru) Твердая дисперсия циннаризина
WO2018093289A1 (ru) Пероральная твердая лекарственная форма и способ ее получения

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180815